Carcinoma

Fujirebio Europe Expands Its Portfolio With Introduction of the Innovative PreCursor-M AnoGYN assay (RUO) for Methylation Testing in Anal Specimens

Retrieved on: 
Tuesday, March 5, 2024

Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.

Key Points: 
  • Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.
  • In analogy with cervical cancer screening, the screening and treatment of HSIL to prevent anal cancer in high-risk groups are under debate.
  • Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer.
  • Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer.

DermBiont Announces 2024 Development Pipeline Update for its First-in-Class Targeted Topical Therapeutics for Seborrheic Keratoses, Basal Cell Carcinomas, and Melasma

Retrieved on: 
Thursday, February 22, 2024

DermBiont currently anticipates that data will be available in Q3 2024.

Key Points: 
  • DermBiont currently anticipates that data will be available in Q3 2024.
  • SKs: DermBiont expects to report data from its CT-213 Phase 2b clinical trial of SM-020 gel 1.0% in Q3 2024.
  • BCCs and SCCISs: DermBiont expects to initiate its CT-217 Phase 2a clinical trial in Q1 2024 and report data in Q3 2024.
  • Melasma: DermBiont anticipates enrolling the first patient in its randomized, observer-blinded, vehicle-controlled CT-214 Phase 2b trial of SM-030 in 138 subjects with melasma in Q2 2024.

Lincoln Property Company, BPGbio, and Cresa Announce 70,000-sq.-ft. Lease at 300 Third Avenue in Waltham

Retrieved on: 
Wednesday, February 21, 2024

ft. of lab and office space at 300 Third Avenue in Waltham, Mass.

Key Points: 
  • ft. of lab and office space at 300 Third Avenue in Waltham, Mass.
  • View the full release here: https://www.businesswire.com/news/home/20240221278304/en/
    300 Third Avenue in Waltham, Massachusetts.
  • 300 Third Avenue is a 143,533-sq.-ft. purpose-built life science building with four stories of laboratory space and 441 on-site parking spaces.
  • Lincoln Property Company (“Lincoln”) is one of the largest diversified real estate services companies with 35 offices across the United States the United Kingdom and Europe.

SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555

Retrieved on: 
Thursday, March 7, 2024

Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions.

Key Points: 
  • Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions.
  • Brandt noted, "Mohs micrographic surgery has been the gold standard of care for the treatment of nonmelanoma skin cancer (NMSC) for more than 50 years.
  • "SkinCure Oncology," Brandt continued, "is helping dermatologists nationwide implement the GentleCure Experience – an advanced, noninvasive treatment for NMSC.
  • The new devices will feature technology for which SkinCure Oncology was recently awarded U.S. patent coverage.

SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug 'SNB-101' on Pancreatic Cancer

Retrieved on: 
Thursday, February 29, 2024

According to SN Bioscience, SNB-101 showed excellent efficacy compared to existing first-line treatments Abraxane® and Onivyde® in pancreatic cancer animal models.

Key Points: 
  • According to SN Bioscience, SNB-101 showed excellent efficacy compared to existing first-line treatments Abraxane® and Onivyde® in pancreatic cancer animal models.
  • Based on this, it has been designated as an orphan drug by the US FDA after application in November last year.
  • Orphan drug designation is a program where the US FDA facilitates the development and approval of treatments for rare/incurable or life-threatening diseases.
  • By receiving an ODD for pancreatic cancer this time, SN Bioscience expects to gain momentum in indication expansion and clinical development.

FDA Grants Fast Track Designation to 9MW2821

Retrieved on: 
Tuesday, February 27, 2024

SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (hereinafter referred to as "ESCC").

Key Points: 
  • SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (hereinafter referred to as "ESCC").
  • 9MW2821 is the world's first Nectin-4-targeting drug to disclose clinical efficacy data for the indication of EC.
  • After injection, 9MW2821 can specifically bind to Nectin-4 on the cell membrane surface, be internalized and release cytotoxic drug, and induce the apoptosis of tumor cells.
  • 9MW2821 is also the first to disclose preliminary clinical efficacy data for the indication of CC among drugs with the same target in the world.

Medical Journal: Image-Guided Superficial Radiation Therapy Is Superior to Superficial Radiation Therapy Without Guidance

Retrieved on: 
Tuesday, February 20, 2024

BURR RIDGE, Ill., Feb. 20, 2024 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer, presented to dermatology patients as the GentleCure™ experience, announced the publication of research, "Image guidance improves freedom from recurrence in superficial radiation therapy for non-melanoma skin cancer," in Advances in Radiation Oncology, a peer-reviewed journal from the American Society for Radiation Oncology (ASTRO).

Key Points: 
  • It shows definitively that the new technology is superior, and represents a seminal moment in the care of skin cancer patients using radiation.
  • This study is the first to rigorously compare SRT to IGSRT, and it covers all the data that exists on IGSRT.
  • Superficial radiation therapy was developed over 100 years ago ( here ) and was the standard therapy for nonmelanoma skin cancer until Mohs micrographic surgery emerged in the 1930's ( here ).
  • IGSRT and the GentleCure experience will be showcased at the upcoming American Academy of Dermatology annual meeting in San Diego, at booth 3555.

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

Retrieved on: 
Thursday, February 15, 2024

LOS ANGELES and AMSTERDAM, Feb. 15, 2024 (GLOBE NEWSWIRE) -- GEDiCube (moving forward RenovaroCube), a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.

Key Points: 
  • Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
  • Cyclomics’ 4th generation liquid biopsy genomics platform is the first truly “Omni-Omic” blood test ready for AI application.
  • Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.
  • The focus is on early cancer- and early recurrence detection, prediction of response to therapy, and personalized treatment, all via liquid biopsy tests.

What are ‘collarium’ sunbeds? Here’s why you should stay away

Retrieved on: 
Wednesday, February 14, 2024

A collarium sunbed emits both UV radiation and a mix of visible wavelength colours to produce a pink or red light.

Key Points: 
  • A collarium sunbed emits both UV radiation and a mix of visible wavelength colours to produce a pink or red light.
  • Like an old-school sunbed, the user lies in it for ten to 20 minute sessions to quickly develop a tan.

Why were sunbeds banned?

  • Commercial sunbeds have been illegal across Australia since 2016 (except for in the Northern Territory) under state-based radiation safety laws.
  • Their dangers were highlighted by young Australians including Clare Oliver who developed melanoma after using sunbeds.
  • Research shows people who have used sunbeds at least once have a 41% increased risk of developing melanoma, while ten or more sunbed sessions led to a 100% increased risk.

How are collarium sunbeds supposed to be different?

  • Australian sellers of collarium sunbeds imply they are safe, but their machine descriptions note the use of UV radiation, particularly UVA.
  • UVA is one part of the spectrum of UV radiation.
  • Evidence shows all types of sunbeds increase the risk of melanoma, including those that use only UVA.

Collagen claims

  • One particularly odd claim about collarium sunbeds is that they stimulate collagen.
  • Collagen is the main supportive tissue in our skin.
  • The reactive oxygen species generated by UVA light damage existing collagen structures and kick off a molecular chain of events that downgrades collagen-producing enzymes and increases collagen-destroying enzymes.
  • Over time, a build-up of degraded collagen fragments in the skin promotes even more destruction.

What about phototherapy?

  • The anti-collagen effects of UVA can also be used to treat thickened scars and keloids.
  • Side-effects of UV phototherapy include tanning, itchiness, dryness, cold sore virus reactivation and, notably, premature skin ageing.

So what happens now?

  • It looks like many collariums are just sunbeds rebranded with red light.
  • Queensland Health is currently investigating whether these salons are breaching the state’s Radiation Safety Act, and operators could face large fines.


Katie Lee receives funding from the National Health and Medical Research Council. Anne Cust receives funding from the National Health and Medical Research Council and Medical Research Future Fund.

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

Retrieved on: 
Wednesday, February 14, 2024

SAN DIEGO and CALGARY, Alberta, Feb. 14, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the expansion of enrollment for the anal cancer cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab (Tecentriq®) in patients with second-line or later unresectable squamous cell carcinoma of the anal canal (SCCA). The study was expanded based on positive data from Stage 1 of the study, presented at the 2nd International Multidisciplinary Anal Cancer Conference (IMACC) in November 2023 (link to the PR, link to the poster).

Key Points: 
  • "These exciting clinical data, which exceed the Simon two-stage success criteria, provide strong support to expand the evaluation of pelareorep in patients with advanced anal cancer.
  • "We begin the Stage 2 expansion with substantial optimism for patients and the potential of pelareorep, especially considering the initial efficacy signal observed for pelareorep-based therapy in pancreatic cancer.
  • There is currently no established standard therapy for patients with anal carcinoma who have failed first-line treatment.
  • Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.